#Bioretec #Finland #Helsinki #financial targets #sales margin

Bioretec Updates Financial Strategy for 2026-2028

In a significant move for transparency and alignment with industry standards, Bioretec has declared its intention to transition to reporting an adjusted sales margin beginning in the first quarter of 2026. This decision marks a pivotal shift in how the Finnish medical device company communicates its financial performance regarding sales profitability, particularly for its implant products.

Understanding the Transition to Adjusted Sales Margin

Previously, Bioretec reported its sales margin by considering total net sales, which included revenue from both implants and related instruments, and subtracted the costs associated with inventory and services. However, the new model focuses solely on net sales derived from implants, providing a clearer picture of the company's operational profitability before accounting for commercialization expenses like sales commissions.

New Calculation Methodology

The recalibration of the sales margin approach is aimed at enhancing the clarity and relevance of Bioretec's financial reports. Under the new methodology, factors recognized below the adjusted sales margin will incorporate fixed external costs, leading to a more straightforward assessment of profitability based on the core products.

Revised Financial Targets for 2026-2028

Bioretec's updated financial aspirations for the strategic period from 2026 to 2028 have been defined as follows:

• - Achieve net sales exceeding EUR 10 million by the end of 2028.
• - Maintain an average adjusted sales margin of over 70% throughout this strategic period.

These targets replace the earlier projections made in December 2025, indicating a strategic pivot in how the company measures its growth and performance.

Market Context and Strategic Implications

The decision to embrace a more industry-standard reporting approach not only positions Bioretec to appeal to investors with a clearer financial outlook but also demonstrates the company’s commitment to operational excellence. This move can be perceived as a proactive strategy to cultivate investor confidence by aligning their reporting with common practices in the medical device sector.

Bioretec has established itself as a leader in biodegradable implant technologies, and thus, maintaining and improving their sales margins is crucial to their long-term profitability and sustainability. With products already making their mark in approximately 40 countries, strengthening financial transparency can further bolster their reputation within the global market.

About Bioretec's Innovations

Bioretec is renowned for its innovative advancements in orthopedic care, primarily through their unique biodegradable implant technologies. Their flagship product line, RemeOs™, crafted from a high-performance magnesium alloy and hybrid composite, heralds a new era in surgical materials.

These implants not only facilitate enhanced fracture healing but also dissolve naturally, minimizing the need for subsequent surgical removals. As of March 2023, RemeOs products have received market authorization in the U.S., as well as CE mark approval in Europe as of January 2025, exemplifying the company’s growth trajectory and commitment to improving patient outcomes.

The Activa product line offers entirely bioabsorbable orthopedic implants that have gained CE and FDA clearance, indicating a broad range of applications for various patient demographics, both adult and pediatric. With these innovations, Bioretec is truly paving the way for developments in orthopedic treatment methodologies, further focusing on integration of absorption for effective healing solutions.

For further information about Bioretec and its groundbreaking work in medical device technology, visit www.bioretec.com.